ABCA1 and atherosclerosis: SDT with 5-aminolevulinic acid as a sonosensitizer (ALA-SDT) activates the PPAR-γ-LXRa/ABCA1 and ABCG1 pathway, increasing cholesterol efflux, induces an anti-inflammatory response, and ultimately reduces the signs of atherosclerosis [342].